| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Division of Molecular Pathology [C. J. D., M. J. U., I. B., M. D., C. C-C.], Departments of Pathology [J. T-F.], Urology [K. P.], and Surgery [A. H.], and Laboratory of Molecular Aspects of Hematopoiesis [C. V. H.], Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
Purpose: The p63 gene, located on chromosome 3q27-28, is a member of the p53 gene family. The product encoded by the p63 gene has been reported to be essential for normal development.
Experimental Design: In this study, we examined the expression pattern of p63 in human normal and tumor tissues by immunohistochemistry using a monoclonal antibody (clone 4A4) that recognizes all p63 splice variants, and by reverse transcription-PCR using isoform-specific primers.
Results: We found that p63 expression was restricted to the nucleus, with a nucleoplasmic pattern. We also observed that the expression was restricted to epithelial cells of stratified epithelia, such as skin, esophagus, exocervix, tonsil, and bladder, and to certain subpopulations of basal cells in glandular structures of prostate and breast, as well as in bronchi. Consistent with the phenotype observed in normal tissues, we found that p63 is expressed predominantly in basal cell and squamous cell carcinomas, as well as transitional cell carcinomas, but not in adenocarcinomas, including those of breast and prostate. Interestingly, thymomas expressed high levels of p63. Moreover, a subset of non-Hodgkin’s lymphoma was also found to express p63. Using isoform-specific reverse transcription-PCR, we found that thymomas express all isoforms of p63, whereas the non-Hodgkin’s lymphoma tended to express the transactivation-competent isoforms. We did not detect p63 expression in a variety of endocrine tumors, germ cell neoplasms, or melanomas. Additionally, soft tissue sarcomas were also found to have undetectable p63 levels.
Conclusions: Our data support a role for p63 in squamous and transitional cell carcinomas, as well as certain lymphomas and thymomas.
This article has been cited by other articles:
|
|
 |
|
  S. Marchini, M. Marabese, E. Marrazzo, P. Mariani, D. Cattaneo, R. Fossati, A. Compagnoni, R. Fruscio, A. A. Lissoni, and M. Broggini {Delta}Np63 expression is associated with poor survival in ovarian cancer Ann. Onc., March 1, 2008; 19(3): 501 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shimomura, M. Wajid, L. Shapiro, and A. M. Christiano P-cadherin is a p63 target gene with a crucial role in the developing human limb bud and hair follicle Development, February 15, 2008; 135(4): 743 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Malaguarnera, V. Vella, G. Pandini, M. Sanfilippo, V. Pezzino, R. Vigneri, and F. Frasca TAp73{alpha} Increases p53 Tumor Suppressor Activity in Thyroid Cancer Cells via the Inhibition of Mdm2-Mediated Degradation Mol. Cancer Res., January 1, 2008; 6(1): 64 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Ferguson-Yates, H. Li, T. K. Dong, J. L. Hsiao, and D. H. Oh Impaired repair of cyclobutane pyrimidine dimers in human keratinocytes deficient in p53 and p63 Carcinogenesis, January 1, 2008; 29(1): 70 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sariya, K. Ruth, R. Adams-McDonnell, C. Cusack, X. Xu, R. Elenitsas, J. Seykora, T. Pasha, P. Zhang, M. Baldassano, et al. Clinicopathologic Correlation of Cutaneous Metastases: Experience From a Cancer Center Arch Dermatol, May 1, 2007; 143(5): 613 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wan, M. Yuan, C. Simpson, K. Allen, F. N.E. Gavins, M. S. Ikram, S. Basu, N. Baksh, E. A. O'Toole, and I. R. Hart Stem/Progenitor Cell-Like Properties of Desmoglein 3dim Cells in Primary and Immortalized Keratinocyte Lines Stem Cells, May 1, 2007; 25(5): 1286 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Malaguarnera, V Vella, R Vigneri, and F Frasca p53 family proteins in thyroid cancer Endocr. Relat. Cancer, March 1, 2007; 14(1): 43 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G M K Tse, P-H Tan, P C W Lui, C B Gilks, C S P Poon, T K F Ma, B K B Law, and W W M Lam The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast J. Clin. Pathol., March 1, 2007; 60(3): 315 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ichimiya and T. Kojima Cellular Networks of Human Thymic Medullary Stromas Coordinated by p53-Related Transcription Factors J. Histochem. Cytochem., November 1, 2006; 54(11): 1277 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Barbieri, L. J. Tang, K. A. Brown, and J. A. Pietenpol Loss of p63 Leads to Increased Cell Migration and Up-regulation of Genes Involved in Invasion and Metastasis. Cancer Res., August 1, 2006; 66(15): 7589 - 7597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. N. Z. Ramalho, A. Ribeiro-Silva, G. D. Cassali, and S. Zucoloto The Expression of p63 and Cytokeratin 5 in Mixed Tumors of the Canine Mammary Gland Provides New Insights into the Histogenesis of These Neoplasms. Vet. Pathol., July 1, 2006; 43(4): 424 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Keyes, H. Vogel, M. I. Koster, X. Guo, Y. Qi, K. M. Petherbridge, D. R. Roop, A. Bradley, and A. A. Mills p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors PNAS, May 30, 2006; 103(22): 8435 - 8440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-C. Nguyen, K. Lefort, A. Mandinova, D. Antonini, V. Devgan, G. Della Gatta, M. I. Koster, Z. Zhang, J. Wang, A. T. di Vignano, et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation Genes & Dev., April 15, 2006; 20(8): 1028 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Yan and X. Chen GPX2, a Direct Target of p63, Inhibits Oxidative Stress-induced Apoptosis in a p53-dependent Manner J. Biol. Chem., March 24, 2006; 281(12): 7856 - 7862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Helton, J. Zhu, and X. Chen The Unique NH2-terminally Deleted ({Delta}N) Residues, the PXXP Motif, and the PPXY Motif Are Required for the Transcriptional Activity of the {Delta}N Variant of p63 J. Biol. Chem., February 3, 2006; 281(5): 2533 - 2542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Foschini, A. Gaiba, R. Cocchi, M. G. Pennesi, and A. Pession p63 Expression in Salivary Gland Tumors: Role of{Delta}Np73L in Neoplastic Transformation International Journal of Surgical Pathology, October 1, 2005; 13(4): 329 - 335. [Abstract] [PDF]
|
|
|
|
|
|
A. A. Mills p53: link to the past, bridge to the future Genes & Dev., September 15, 2005; 19(18): 2091 - 2099. [Full Text] [PDF]
|
|
|
|
 |
|
 D.-Y. Wang, C.-C. Cheng, M.-H. Kao, Y.-J. Hsueh, D. H. K. Ma, and J.-K. Chen Regulation of Limbal Keratinocyte Proliferation and Differentiation by TAp63 and {Delta}Np63 Transcription Factors Invest. Ophthalmol. Vis. Sci., September 1, 2005; 46(9): 3102 - 3108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Johnson, E. M. Shepard, and K. W. Scotto Differential Regulation of MDR1 Transcription by the p53 Family Members: ROLE OF THE DNA BINDING DOMAIN J. Biol. Chem., April 8, 2005; 280(14): 13213 - 13219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Barbieri, C. A. Perez, K. N. Johnson, K. A. Ely, D. Billheimer, and J. A. Pietenpol IGFBP-3 Is a Direct Target of Transcriptional Regulation by {Delta}Np63{alpha} in Squamous Epithelium Cancer Res., March 15, 2005; 65(6): 2314 - 2320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. M. Moll and N. Slade p63 and p73: Roles in Development and Tumor Formation Mol. Cancer Res., July 1, 2004; 2(7): 371 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Westfall and J. A. Pietenpol p63: molecular complexity in development and cancer Carcinogenesis, June 1, 2004; 25(6): 857 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O. Stuart, W. Wachsman, C. C. Berry, J. Wang-Rodriguez, L. Wasserman, I. Klacansky, D. Masys, K. Arden, S. Goodison, M. McClelland, et al. In silico dissection of cell-type-associated patterns of gene expression in prostate cancer PNAS, January 13, 2004; 101(2): 615 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Barbieri, C. E. Barton, and J. A. Pietenpol {Delta}Np63{alpha} Expression Is Regulated by the Phosphoinositide 3-Kinase Pathway J. Biol. Chem., December 19, 2003; 278(51): 51408 - 51414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Dianzani, E Garelli, P Gustavsson, A Carando, B Gustafsson, N Dahl, and G Anneren Rapp-Hodgkin and AEC syndromes due to a new frameshift mutation in the TP63 gene J. Med. Genet., December 1, 2003; 40(12): e133 - 133. [Full Text]
|
|
|
|
 |
|
 U. M. Moll The Role of p63 and p73 in Tumor Formation and Progression: Coming of Age Toward Clinical Usefulness: Commentary re: F. Koga et al., Impaired p63 Expression Associates with Poor Prognosis and Uroplakin III Expression in Invasive Urothelial Carcinoma of the Bladder. Clin. Cancer Res., 9: 5501-5507, 2003, and P. Puig et al., p73 Expression in Human Normal and Tumor Tissues: Loss of p73{alpha} Expression Is Associated with Tumor Progression in Bladder Cancer. Clin. Cancer Res., 9: 5642-5651, 2003. Clin. Cancer Res., November 15, 2003; 9(15): 5437 - 5441. [Full Text] [PDF]
|
|
|
|
|
|
P. Puig, P. Capodieci, M. Drobnjak, D. Verbel, C. Prives, C. Cordon-Cardo, and C. J. Di Como p73 Expression in Human Normal and Tumor Tissues: Loss of p73{alpha} Expression Is Associated with Tumor Progression in Bladder Cancer Clin. Cancer Res., November 15, 2003; 9(15): 5642 - 5651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Langner, M. Ratschek, O. Tsybrovskyy, L. Schips, and R. Zigeuner P63 Immunoreactivity Distinguishes Upper Urinary Tract Transitional-cell Carcinoma and Renal-cell Carcinoma Even in Poorly Differentiated Tumors J. Histochem. Cytochem., August 1, 2003; 51(8): 1097 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. H. Galindo, C. Theiss, K.-P. Steuhl, and D. Meller Expression of {Delta}Np63 in Response to Phorbol Ester in Human Limbal Epithelial Cells Expanded on Intact Human Amniotic Membrane Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 2959 - 2965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Westfall, D. J. Mays, J. C. Sniezek, and J. A. Pietenpol The {Delta}Np63{alpha} Phosphoprotein Binds the p21 and 14-3-3{sigma} Promoters In Vivo and Has Transcriptional Repressor Activity That Is Reduced by Hay-Wells Syndrome-Derived Mutations Mol. Cell. Biol., April 1, 2003; 23(7): 2264 - 2276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bilal, A. Handra-Luca, J.-C. Bertrand, and P. J. Fouret p63 Is Expressed in Basal and Myoepithelial Cells of Human Normal and Tumor Salivary Gland Tissues J. Histochem. Cytochem., February 1, 2003; 51(2): 133 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Urist, C. J. Di Como, M.-L. Lu, E. Charytonowicz, D. Verbel, C. P. Crum, T. A. Ince, F. D. McKeon, and C. Cordon-Cardo Loss of p63 Expression Is Associated with Tumor Progression in Bladder Cancer Am. J. Pathol., October 1, 2002; 161(4): 1199 - 1206. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
